Journal of International Psychiatry

【Abstract】 Objective: To study the droperidol thioxanthene melitracen (deanxit) combined with paroxetine hydrochloride in the treatment of post-stroke depression clinical effects. Methods: our hospital in 124 cases of patients with depression after stroke, randomized study group and control group, 62 cases in each group.Two groups of stroke treatment, conventional treatment of the observation group on the basis of application of deanxit combined with paroxetine hydrochloride, controls the simple application of deanxit in treatment.6 weeks after comparing two sets of Hamilton depression scale score (HAMD), ability of daily living (ADL) and the patients treatment and compliance.Results: before treatment, the two groups score was not statistically significant, (P < 0.05). After treatment, observation group HAMD score was significantly lower than that of the control group, ADL score was significantly lower than that of the control group observed in the treatment group the effective rate was 96.88%) was significantly higher than that of the control group of 81.67%; clinical treatment compliance was 95.31% was significantly higher than that of control group (60.00%), the scores of the two groups was statistically significant, P < 0.05. Conclusion: Droperidol thioxanthene melitracen tablets combined with paroxetine hydrochloride in treating depression after stroke can significantly ease symptoms of depression and increase treatment compliance and living quality of patients and adverse reactions, medication safety, than the simple application of deanxit therapy, treatment is more effective in clinical practice.

【Key words】 Droperidol thioxanthene melitracen; Pa Rossi Dean; Stroke; Depression